On Café Pharma message boards, the drug industry’s online water cooler, anonymous sales reps are sounding off on the Physician Payment Sunshine Act and its implications for their battered profession.
On Café Pharma message boards, the drug industry’s online water cooler, anonymous sales reps are sounding off on the Physician Payment Sunshine Act and its implications for their battered profession. Here’s a selection from a thread that PharmExec came across, edited for spelling, punctuation, and coherence:
“It’s been talked about for the last couple of years. Now that it’s finally here, what are your [physician] offices actually saying? Are you still going to bother with lunches?”
“Offices will start canceling all lunches. The reps will feel it in their pocket too. No more bringing home free dinners to feed the family.”
“It’s not a problem as of yet, but wait until the media starts talking and/or printing the monies spent then it will be a different story.”
“Wait ‘til the local paper starts publishing how much money is spent on good old ‘Doc High Writer’ ($200 a day for lunch/breakfast, X 4 days a week, 52 weeks a year, gosh that sounds like a lot, it is), you’ll see him on the 6 o’clock news for 20 seconds, trying to explain the great educational interaction he receives from us reps. But the lunch room will be shut down.”
“A few years ago there was a fire drill when docs discovered they could block their data-three docs in my territory did it. The only people who will be affected are the speakers for [Novo Nordisk] who get $100K-plus per year. I will make sure that certain people get a photocopy of certain documents in order to convince them of certain things.”
“I left [Sanofi-Aventis] for medical device sales and never looked back. We don’t do lunches, dinner programs, have iPads, and give away pens, post-it notes, clipboards, wall clocks, or samples in order to make our sales calls more effective. It’s sad that you have trained your customers to expect these things and now you are worried that pharma reps will have to rely on their capabilities of selling without them.”
“Lunches are shutting down, people. Once a doctor exceeds $100 reported of food annually, their record will go public for all to see just how much money they receive in free food from sales reps.”
“This is not just a pharma thing either. Any healthcare related vendors are liable.”
“Unfortunately, it doesn’t matter if meals are under $10. Everything gets posted once the doc hits $100 total for the year. I can almost feel the doors closing once docs figure that out, and the media gets a hold of the data.”
“Basically, anyone who is in a so-called sales position, one that UPS or Fed-Ex can do a better job at is impacted.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.